Migraine: Preventive treatment

Handbook of Clinical Neurology

Volumn 97, Issue C, 2010, Pages 337-354

  Silberstein, Stephen D ^a  

^a JEFFERSON HEADACHE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

HUMAN; MIGRAINE DISORDERS;

ADRENERGIC BETA-ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; MIGRAINE DISORDERS;

EID: 77956269767     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(10)97027-9     Document Type: Book

References (130)

1. Adelman L.C., Adelman J.U., Von Seggern R., et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective sutdy in a clinical setting. Headache 2000, 40:572-580.
2. Adly C., Straumanis J., Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992, 32:101-104.
3. Albers G.W., Simon L.T., Hamik A., et al. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 1989, 29:215-218.
4. Andersson P.G., Dahl S., Hansen J.H., et al. Prophylactic treatment of classical and nonclassical migraine with metoprolol: a comparison with placebo. Cephalalgia 1983, 3:207-212.
5. Ansell E., Fazzone T., Festenstein R., et al. Nimodipine in migraine prophylaxis. Cephalalgia 1988, 8:269-272.
6. Ayata C., Jin H., Kudo C., et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006, 59:652-661.
7. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. The Pharmacological Basis of Therapeutics 1990, 383-435. Pergamon, New York. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
8. Bana D.S., MacNeal P.S., LeCompte P.M., et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974, 88:640-655.
9. Barlow C.F. Headaches and Migraine in Children 1984, JB lippincott, Philadelphia, PA.
10. Bowden C.L., Brugger A.M., Swann A.C. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994, 271:918-924.
11. Bradley D.P., Smith M.I., Netsiri C., et al. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and tonabersat. Exp Neurol 2001, 172:342-353.
12. Brandes J.L., Saper J.R., Diamond M., et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965-973.
13. Bulut S., Berilgen M.S., Baran A., et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004, 107:44-48.
14. Capildeo R., Rose F.C. Single-dose pizotifen, 1.5mg nocte: a new approach in the prophylaxis of migraine. Headache 1982, 22:272-275.
15. Chen W.T., Fuh J.L., Lu S.R., et al. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache 2001, 41:823-825.
16. Cortelli P., Sacquegna T., Albani F., et al. Propranolol plasma levels and relief of migraine. Arch Neurol 1985, 42:46-48.
17. Couch J.R., Ziegler D., Hassanein R. Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976, 26:121-127.
18. Coulam C.B., Annagers J.R. New anticonvulsants reduce the efficacy of oral contraception. Epilepsia 1979, 20:519-525.
19. Curran D.A., Lance J.W. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry 1964, 27:463-469.
20. Curran D.A., Hinterberger H., Lance J.W. Methysergide. Res Clin Stud Headache 1967, 1:74-122.
21. Deweerdt C.J., Bootsma H.P., Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of feverfew preparation. Phytomedicine 1996, 3:225-230.
22. Diamond S., Medina J.L. Double-blind study of propranolol for migraine prophylaxis. Headache 1976, 16:24-27.
23. Diamond S., Solomon G.D., Freitag F.G., et al. Long-acting propranolol in the prophylaxis of migraine. Headache 1987, 27:70-72.
24. Dichgans M., Freilinger T., Eckstein G., et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005, 366:371-377.
25. Diener H.C., Hartung E., Chrubasik J., et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001, 21:120-128.
26. Diener H.C., Matias-Guiu J., Hartung E., et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002, 22:209-221.
27. Diener H.C., Rahlfs V.W., Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004, 51:89-97.
28. Diener H.C., Tfelt-Hansen P., Dahlof C., et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004, 251:943-950.
29. 2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005, 25:1031-1041.
30. Dimitriadou V., Buzzi M.G., Theoharides T.C., et al. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992, 48:187-203.
31. Dodick D.W., Silberstein S.D., Frietag F. Topiramate versus amitriptyline for migraine prophylaxis: a multicenter randomized, double-blind, parallel treatment group trial. Cephalalgia 2007, 26:1373.: (Abstract).
32. Elkind A.H., Friedman A.P., Bachman A., et al. Silent retroperitoneal fibrosis associated with methysergide therapy. JAMA 1968, 206:1041-1044.
33. Etemad L.R., Wang W., Globe D., et al. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 2005, 11:137-144.
34. Evers S., Afra J., Frese A., et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006, 13:560-572.
35. Featherstone H.J. Low dose propranolol therapy for aborting acute migraine. West J Med 1983, 138:416-417.
36. Feinmann C. Pain relief by antidepressants: possible modes of action. Pain 1985, 23:1-8.
37. Forsythe I., Hockaday J.M. Management of childhood migraine. Migraine in Childhood 1988, 63-74. Butterworths, London. J.M. Hockaday (Ed.).
38. Freitag F.G., Diamond S., Diamond M., et al. Divalproex in the long-term treatment of chronic daily headache. Headache 2001, 41:271-278.
39. Freitag F.G., Collins S.D., Carlson H.A., et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652-1659.
40. Freitag F.G., Forde G., Neto W., et al. Topiramate effectively prevents migraine: analyzing pooled data from pivotal controlled trials. Analysis of pooled data from two pivotal controlled trials on the efficacy of topiramate in the prevention of migraine. J Am Osteopath Assoc 2007, 107:251-258.
41. Frishman W.H. Beta adrenergic blocker withdrawal. Am J Cardiol 1987, 59:32F.
42. Gelmers H.J. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 1983, 23:106-109.
43. Gerber W.G., Diener H., Scholz E., et al. Responders and nonresponders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Cephalalgia 1991, 11:37-45.
44. Gold L., Black T., Arnold G., et al. Cortical spreading depression-associated hyperemia in rats: involvement of serotonin. Brain Res 1998, 783:1983.
45. Graham J. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967, 254:1-12.
46. Graham J.R., Suby H.I., LeCompte P.R., et al. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966, 274:360-368.
47. Gray R.N., Goslin R.E., McCrory D.C., et al. Drug treatments for the prevention of migraine headache 1999, Prepared for the Agency for Health Care Policy and Research, Contract No. 290-94-2025. Available from the National Technical Information Service, Accession No. 127953.
48. Grotemeyer K.H., Scharafinski H.W., Schlake H.P., et al. Acetylsalicylic acid vs metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1990, 30:639-641.
49. Hanston P.P., Horn J.R. Drug interaction. Newsletter 1985, 5:7-10.
50. Headache Classification Committee The international classification of headache disorders. Cephalalgia 2004, 24:1-160. 2nd edition.
51. Jensen R., Brinck T., Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994, 44:647-651.
52. Johnson E.S., Kadam N.P., Hylands D.M., et al. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985, 291:569-573.
53. Kandere-Grzybowska K., Gheorghe D., Priller J., et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res 2003, 980:213-220.
54. Kangasniemi P., Andersen A.R., Andersson P.G., et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987, 7:231-238.
55. Kishore-Kumar R., Max M.B., Schafer S.C., et al. Desipramine relieves post-herpetic neuralgia. Clin Pharmacol Ther 1990, 47:305-312.
56. Klapper J.A. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997, 17:103-108.
57. Koella W.P. CNS-related (side-)effects of β-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 1985, 28:55-63.
58. Lamsudin R., Sadjimin T. Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. Headache 1993, 33:335-338.
59. Lance J.W., Fine R.D., Curran D.A. An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Aust 1963, 1:814-818.
60. Leandri M., Rigardo S., Schizzi R., et al. Migraine treatment with nicardipine. Cephalalgia 1990, 10:111-116.
61. Lipton R.B., Gobel H., Einhaupl K.M., et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004, 63:2240-2244.
62. Lipton R.B., Diamond M., Freitag F., et al. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2005, 45:792-793. (Abstract).
63. Markley H.G., Cleronis J.C.D., Piepko R.W. Verapamil prophylactic therapy of migraine. Neurology 1984, 34:973-976.
64. Mathew N.T. Gabapentin in migraine prophylaxis. Cephalalgia 1996, 16:367.
65. Mathew N.T., Saper J.R., Silberstein S.D., et al. Migraine prophylaxis with divalproex. Arch Neurol 1995, 52:281-286.
66. Mathew N.T., Saper J.R., Silberstein S.D., et al. Prophylaxis of migraine headaches with divalproex sodium. Arch Neurol 1995, 52:281-286.
67. Mathew N., Saper J., Magnus-Miller L. Efficacy and safety of gabapentin (Neurontin®) in migraine prophylaxis 1998, (Abstract).
68. McArthur J.C., Marek K., Pestronk A., et al. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side-effects. Neurology 1989, 39:284-286.
69. Migraine-Nimodipine European Study Group (MINES) European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989, 29:633-638.
70. Murphy J.J., Heptinstall S., Mitchell J.R. Randomized double-blind placebo controlled trial of feverfew in migraine prevention. Lancet 1988, 2:189-192.
71. Olsson J.E., Behring H.C., Forssman B., et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. Acta Neurol Scand 1984, 70:160-180.
72. 2+ channel gene CACNLA4. Cell Tiss Res 1996, 87:543-552.
73. Oshinsky M.L., Luo J. Neurochemistry of a rat migraine model. Headache 2006, 46(Suppl. 1):S39-S44.
74. Palevitch D., Earon G., Carusso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997, 11:508-511.
75. Panerai A.E., Monza G., Movilia P., et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990, 82:34-38.
76. Peatfield R. Drugs acting by modification of serotonin function. Headache 1986, 26:129-131.
77. Pedersen E., Moller C.E. Methysergide in migraine prophylaxis. Pharmacol Ther 1966, 7:520-526.
78. Pellock J.M., Willmore L.J. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991, 41:961-964.
79. Pfaffenrath V., Diener H.C., Fischer M., et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicenter, randomized, placebo-controlled, dose-response study. Cephalalgia 2002, 22:523-532.
80. Pradalier A., Serratrice G., Colard M., et al. Long-acting propranolol on migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 1989, 9:247-253.
81. Rabkin R., Stables D.P., Levin N.W., et al. The prophylactic value of propranolol in angina pectoris. Am J Cardiol 1966, 370-383.
82. Ramadan N.M. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004, 8:91-95.
83. Ramadan N.M., Silberstein S.D., Freitag F.G., et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Neurology 2000, Available online at:. http://www.neurology.org.
84. Rao B.S., Das D.G., Taraknath V.R., et al. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000, 48:223-226.
85. Raskin N.H. Headache 1988, Churchill-Livingstone, New York.
86. Raskin N.H. Migraine treatment. Headache 1988, Churchill-Livingstone, New York. N.H. Raskin (Ed.).
87. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 1990, 65:1227-1236.
88. Riopelle R., McCans J.L. A pilot study of the calcium channel antagonist diltiazem in migraine syndrome prophylaxis. Can J Neurol Sci 1982, 9:269.
89. Rozen T.D., Oshinsky M.L., Gebeline C.A., et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002, 22:137-141.
90. Ryan R.E. Double-blind crossover comparison of BC105, methysergide, and placebo in the prophylaxis of migraine headache. Headache 1968, 8:118-126.
91. Sachedo R.C., Reife R.A., Lim P., et al. Topiramate monotherapy for partial onset seizures. Epilepsia 1997, 38:294-300.
92. Sandor P.S., diClemente L., Coppola G., et al. Coenzyme Q10 for migraine prophylaxis: a randomized controlled trial. Cephalalgia 2003, 23:577.: (Abstract).
93. Saper J.R., Silberstein S.D., Lake A.E., et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994, 34:497-502.
94. Schoenen J., Jacquy J., Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998, 50:466-470.
95. Shank R.P., Gardocki J.F., Vaught J.L., et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994, 35:450-460.
96. Shekelle R.B., Ostfeld A.M. Methysergide in the migraine syndrome. Clin Pharmacol Ther 1964, 5:201-204.
97. Shukla R., Garg R.K., Nag D., et al. Nifedipine in migraine and tension headache: a randomized double-blind crossover study. J Assoc Phys India 1995, 43:770-772.
98. Silberstein S.D. Divalproex sodium in headache - literature review and clinical guidelines. Headache 1996, 36:547-555.
99. Silberstein S.D. Migraine and pregnancy. Neurol Clin 1997, 15:209-231.
100. Silberstein S.D. Control of topiramate-induced paresthesias with supplemental potassium (letter). Headache 2002, 42:85.
101. Silberstein S.D. Migraine pathophysiology and its clinical implications. Cephalalgia 2004, 24(Suppl. 2):2-7.
102. Silberstein S.D. Practice parameter: evidence-based guidelines for treatment of migraine headache. Neurology 2010, on behalf of the Quality Standards Improvement Committee, (in press).
103. Silberstein S.D., Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000, 54:1553.
104. Silberstein S.D., Silberstein M.M. New concepts in the pathogenesis of headache. Part II. Pain Mgt 1990, 3:334-342.
105. Silberstein S.D., Lipton R.B., Breslau N. Migraine: association with personality characteristics and psychopathology. Cephalalgia 1995, 15:337-369.
106. Silberstein S.D., Lipton R.B., Goadsby P.J. Migraine: diagnosis and treatment. Headache in Clinical Practice 1998, 61-90. Isis Medical Media, Oxford. S.D. Silberstein, R.B. Lipton, P.J. Goadsby (Eds.).
107. Silberstein S.D., Winner P.K., Chmiel J.J. Migraine preventive medication reduces resource utilization. Headache 2003, 43:171-178.
108. Silberstein S.D., Bhattacharaya S., Neto W., et al. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Arch Neurol 2004, 61:490-495.
109. Silberstein S., Diamond S., Loder E., et al. Prevalence of migraine sufferers who are candidates for preventive therapy: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2005, 45:770-771. (Abstract).
110. Silberstein S.D., Feliu A.L., Rupow M.F.T., et al. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache 2007, 47:500-510.
111. Silberstein S., Saper J., Berenson F., et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008, 70:548-555.
112. Smith R., Schwartz A. Diltiazem prophylaxis in refractory migraine. N Engl J Med 1984, 310:1327-1328.
113. Smyth G.A., Lazarus L. Suppression of growth hormone secretion by melatonin and cyproheptadine. J Clin Invest 1974, 54:116-121.
114. Solomon G.D. Verapamil and propranolol in migraine prophylaxis: a double-blind crossover study. Headache 1986, 26:325.
115. Solomon G.D. Management of the headache patient with medical illness. Clin J Pain 1989, 5:95-99.
116. Sorensen P.S., Larsen B.H., Rasmussen M.J., et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991, 31(10):650-657.
117. Steardo L., Bonuso S., DiStasio E., et al. Selective and nonselective beta-blockers: are both effective in prophylaxis of migraine? A clinical trial versus methysergide. Acta Neurol 1982, 4:196-204.
118. Steiner T.J., Findley L.J., Yuen A.W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997, 17:109-112.
119. Storer R.J., Goadsby P.J. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology 2003, 60:A238. (Abstract).
120. Sudilovsky A., Elkind A.H., Ryan R.E., et al. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache 1987, 27:421-426.
121. Tfelt-Hansen P., Lipton R.B. Prioritizing treatment. The Headaches 1993, 359-362. Raven Press, New York. J. Olesen, P. Tfelt-Hansen, K.M.A. Welch (Eds.).
122. Thomson Healthcare Physicians' Desk Reference 2003, Thomson PDR, Montvale, NJ.
123. Vainionpaa L.K., Rattya J., Knip M., et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999, 45:444-450.
124. Vilming S., Standnes B., Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalalgia 1985, 5:17-23.
125. Vogler B.K., Pittler M.H., Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998, 18:704-708.
126. Wauquier A., Ashton D., Marranes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 1985, 5:119-120.
127. Weber R.B., Reinmuth O.M. The treatment of migraine with propranolol. Neurology 1972, 22:366-369.
128. Weilburg J.B., Rosenbaum J.F., Biederman J., et al. Fluoxetine added to nonMAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989, 50:447-449.
129. Wessely P., Baumgartner C., Klinger D., et al. Preliminary results of a double-blind study with the new migraine prophylactic drug gabapentin. Cephalalgia 1987, 7:477-478.
130. Wheeler S.D. Lamotrigine efficacy in migraine prevention. Cephalalgia 2001, 21:374. (Abstract).